108,100 Shares in Orthofix Medical Inc. (NASDAQ:OFIX) Bought by HighVista Strategies LLC

HighVista Strategies LLC purchased a new position in Orthofix Medical Inc. (NASDAQ:OFIX - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 108,100 shares of the medical device company's stock, valued at approximately $1,689,000. HighVista Strategies LLC owned approximately 0.28% of Orthofix Medical as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. Vanguard Group Inc. raised its holdings in shares of Orthofix Medical by 0.5% in the first quarter. Vanguard Group Inc. now owns 2,008,816 shares of the medical device company's stock worth $29,168,000 after buying an additional 9,150 shares during the period. Price T Rowe Associates Inc. MD lifted its position in shares of Orthofix Medical by 3.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 32,957 shares of the medical device company's stock valued at $479,000 after buying an additional 1,236 shares during the last quarter. Bank of New York Mellon Corp grew its position in shares of Orthofix Medical by 6.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 143,772 shares of the medical device company's stock worth $1,906,000 after buying an additional 9,118 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Orthofix Medical by 25.5% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,435 shares of the medical device company's stock worth $125,000 after purchasing an additional 1,919 shares during the last quarter. Finally, nVerses Capital LLC purchased a new position in Orthofix Medical during the 2nd quarter worth $27,000. 89.76% of the stock is owned by institutional investors.

Orthofix Medical Stock Up 0.2 %

NASDAQ OFIX traded up $0.03 during mid-day trading on Tuesday, reaching $19.34. 164,565 shares of the stock were exchanged, compared to its average volume of 327,308. Orthofix Medical Inc. has a 1 year low of $10.28 and a 1 year high of $20.73. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.11 and a current ratio of 2.39. The business's 50 day moving average is $16.99 and its 200-day moving average is $15.85.

Wall Street Analyst Weigh In

OFIX has been the topic of several recent analyst reports. Stifel Nicolaus upgraded shares of Orthofix Medical from a "hold" rating to a "buy" rating and upped their price objective for the company from $18.00 to $24.00 in a report on Friday, November 8th. Roth Mkm restated a "buy" rating and issued a $22.00 price objective (up from $20.00) on shares of Orthofix Medical in a research note on Friday, November 8th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to MarketBeat.com, Orthofix Medical has an average rating of "Moderate Buy" and an average target price of $23.00.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.